Frontiers in Immunology (Oct 2020)
Perspective for Precision Medicine for Tuberculosis
- Christoph Lange,
- Christoph Lange,
- Christoph Lange,
- Christoph Lange,
- Christoph Lange,
- Rob Aarnoutse,
- Dumitru Chesov,
- Dumitru Chesov,
- Dumitru Chesov,
- Dumitru Chesov,
- Reinout van Crevel,
- Stephen H. Gillespie,
- Hans-Peter Grobbel,
- Hans-Peter Grobbel,
- Hans-Peter Grobbel,
- Barbara Kalsdorf,
- Barbara Kalsdorf,
- Barbara Kalsdorf,
- Barbara Kalsdorf,
- Irina Kontsevaya,
- Irina Kontsevaya,
- Irina Kontsevaya,
- Arjan van Laarhoven,
- Tomoki Nishiguchi,
- Anna Mandalakas,
- Matthias Merker,
- Matthias Merker,
- Matthias Merker,
- Stefan Niemann,
- Stefan Niemann,
- Stefan Niemann,
- Niklas Köhler,
- Niklas Köhler,
- Niklas Köhler,
- Jan Heyckendorf,
- Jan Heyckendorf,
- Jan Heyckendorf,
- Maja Reimann,
- Maja Reimann,
- Maja Reimann,
- Morten Ruhwald,
- Patricia Sanchez-Carballo,
- Patricia Sanchez-Carballo,
- Patricia Sanchez-Carballo,
- Dominik Schwudke,
- Dominik Schwudke,
- Dominik Schwudke,
- Franziska Waldow,
- Franziska Waldow,
- Andrew R. DiNardo
Affiliations
- Christoph Lange
- Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
- Christoph Lange
- German Center for Infection Research (DZIF) Partner Site Borstel-Hamburg-Lübeck-Riems, Borstel, Germany
- Christoph Lange
- Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany
- Christoph Lange
- Cluster of Excellence Precision Medicine in Chronic Inflammation, Kiel, Germany
- Christoph Lange
- Department of Medicine, Karolinska Institute, Stockholm, Sweden
- Rob Aarnoutse
- Department of Internal Medicine, Radboud Center of Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, Netherlands
- Dumitru Chesov
- Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
- Dumitru Chesov
- German Center for Infection Research (DZIF) Partner Site Borstel-Hamburg-Lübeck-Riems, Borstel, Germany
- Dumitru Chesov
- Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany
- Dumitru Chesov
- Department of Pulmonology and Allergology, Nicolae Testemitanu University of Medicine and Pharmacy, Chisinau, Moldova
- Reinout van Crevel
- Department of Internal Medicine, Radboud Center of Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, Netherlands
- Stephen H. Gillespie
- School of Medicine, University of St Andrews, St Andrews, United Kingdom
- Hans-Peter Grobbel
- Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
- Hans-Peter Grobbel
- German Center for Infection Research (DZIF) Partner Site Borstel-Hamburg-Lübeck-Riems, Borstel, Germany
- Hans-Peter Grobbel
- Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany
- Barbara Kalsdorf
- Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
- Barbara Kalsdorf
- German Center for Infection Research (DZIF) Partner Site Borstel-Hamburg-Lübeck-Riems, Borstel, Germany
- Barbara Kalsdorf
- Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany
- Barbara Kalsdorf
- Cluster of Excellence Precision Medicine in Chronic Inflammation, Kiel, Germany
- Irina Kontsevaya
- Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
- Irina Kontsevaya
- German Center for Infection Research (DZIF) Partner Site Borstel-Hamburg-Lübeck-Riems, Borstel, Germany
- Irina Kontsevaya
- Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany
- Arjan van Laarhoven
- Department of Internal Medicine, Radboud Center of Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, Netherlands
- Tomoki Nishiguchi
- The Global Tuberculosis Program, Texas Children's Hospital, Immigrant and Global Health, Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States
- Anna Mandalakas
- The Global Tuberculosis Program, Texas Children's Hospital, Immigrant and Global Health, Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States
- Matthias Merker
- German Center for Infection Research (DZIF) Partner Site Borstel-Hamburg-Lübeck-Riems, Borstel, Germany
- Matthias Merker
- Cluster of Excellence Precision Medicine in Chronic Inflammation, Kiel, Germany
- Matthias Merker
- 0Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany
- Stefan Niemann
- German Center for Infection Research (DZIF) Partner Site Borstel-Hamburg-Lübeck-Riems, Borstel, Germany
- Stefan Niemann
- Cluster of Excellence Precision Medicine in Chronic Inflammation, Kiel, Germany
- Stefan Niemann
- 0Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany
- Niklas Köhler
- Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
- Niklas Köhler
- German Center for Infection Research (DZIF) Partner Site Borstel-Hamburg-Lübeck-Riems, Borstel, Germany
- Niklas Köhler
- Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany
- Jan Heyckendorf
- Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
- Jan Heyckendorf
- German Center for Infection Research (DZIF) Partner Site Borstel-Hamburg-Lübeck-Riems, Borstel, Germany
- Jan Heyckendorf
- Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany
- Maja Reimann
- Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
- Maja Reimann
- German Center for Infection Research (DZIF) Partner Site Borstel-Hamburg-Lübeck-Riems, Borstel, Germany
- Maja Reimann
- Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany
- Morten Ruhwald
- 1Foundation of Innovative New Diagnostics (FIND), Geneva, Switzerland
- Patricia Sanchez-Carballo
- Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
- Patricia Sanchez-Carballo
- German Center for Infection Research (DZIF) Partner Site Borstel-Hamburg-Lübeck-Riems, Borstel, Germany
- Patricia Sanchez-Carballo
- Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany
- Dominik Schwudke
- German Center for Infection Research (DZIF) Partner Site Borstel-Hamburg-Lübeck-Riems, Borstel, Germany
- Dominik Schwudke
- 2Bioanalytical Chemistry, Priority Area Infection, Research Center Borstel, Leibniz Lung Center, Borstel, Germany
- Dominik Schwudke
- 3Airway Research Center North, German Center for Lung Research (DZL), Borstel, Germany
- Franziska Waldow
- German Center for Infection Research (DZIF) Partner Site Borstel-Hamburg-Lübeck-Riems, Borstel, Germany
- Franziska Waldow
- 2Bioanalytical Chemistry, Priority Area Infection, Research Center Borstel, Leibniz Lung Center, Borstel, Germany
- Andrew R. DiNardo
- The Global Tuberculosis Program, Texas Children's Hospital, Immigrant and Global Health, Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States
- DOI
- https://doi.org/10.3389/fimmu.2020.566608
- Journal volume & issue
-
Vol. 11
Abstract
Tuberculosis is a bacterial infectious disease that is mainly transmitted from human to human via infectious aerosols. Currently, tuberculosis is the leading cause of death by an infectious disease world-wide. In the past decade, the number of patients affected by tuberculosis has increased by ~20 percent and the emergence of drug-resistant strains of Mycobacterium tuberculosis challenges the goal of elimination of tuberculosis in the near future. For the last 50 years, management of patients with tuberculosis has followed a standardized management approach. This standardization neglects the variation in human susceptibility to infection, immune response, the pharmacokinetics of drugs, and the individual duration of treatment needed to achieve relapse-free cure. Here we propose a package of precision medicine-guided therapies that has the prospect to drive clinical management decisions, based on both host immunity and M. tuberculosis strains genetics. Recently, important scientific discoveries and technological advances have been achieved that provide a perspective for individualized rather than standardized management of patients with tuberculosis. For the individual selection of best medicines and host-directed therapies, personalized drug dosing, and treatment durations, physicians treating patients with tuberculosis will be able to rely on these advances in systems biology and to apply them at the bedside.
Keywords